Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Catarsi, Paolo"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł:
Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Autorzy:
Abbà C; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Campanelli R; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Catarsi P; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Villani L; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Abbonante V; Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Sesta MA; Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Barosi G; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Rosti V; Center for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Massa M; Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Aug 01; Vol. 14 (8), pp. e0220189. Date of Electronic Publication: 2019 Aug 01 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Severity of Illness Index*
Antigens, CD34/*metabolism
Primary Myelofibrosis/*pathology
STAT5 Transcription Factor/*genetics
STAT5 Transcription Factor/*metabolism
Tumor Suppressor Proteins/*genetics
Tumor Suppressor Proteins/*metabolism
Adult ; Aged ; Calreticulin/genetics ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Janus Kinase 2/genetics ; Male ; Middle Aged ; Phosphorylation ; Primary Myelofibrosis/genetics ; Primary Myelofibrosis/metabolism ; Prognosis
Czasopismo naukowe
Tytuł:
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.
Autorzy:
Campanelli R; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Fois G; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Catarsi P; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Poletto V; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Villani L; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Erba BG; Vascular Biology Group, IFOM, FIRC Institute of Molecular Oncology, Milano, Italy.
Maddaluno L; Vascular Biology Group, IFOM, FIRC Institute of Molecular Oncology, Milano, Italy.
Jemos B; Unit of Hepatopancreatic Surgery, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Salmoiraghi S; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Guglielmelli P; Center for Research and Innovation for Myeloproliferative Neoplasms-CRIMM, AOU Careggi, and Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Abbonante V; Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Di Buduo CA; Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Balduini A; Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Iurlo A; Oncohematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, University of Milano, Milano, Italy.
Barosi G; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Rosti V; Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Massa M; Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Pokaż więcej
Corporate Authors:
AGIMM Investigators
Źródło:
PloS one [PLoS One] 2016 Jun 09; Vol. 11 (6), pp. e0156990. Date of Electronic Publication: 2016 Jun 09 (Print Publication: 2016).
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Monocytes/*metabolism
Neovascularization, Pathologic/*metabolism
Primary Myelofibrosis/*metabolism
Receptor, TIE-2/*metabolism
Spleen/*metabolism
Aged ; Case-Control Studies ; Cell Differentiation ; Female ; Humans ; Male ; Middle Aged ; Monocytes/pathology ; Primary Myelofibrosis/pathology ; Primary Myelofibrosis/surgery ; Spleen/pathology ; Splenectomy
Czasopismo naukowe
Tytuł:
JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.
Autorzy:
Catarsi P; Center for the Study and Treatment of Myelofibrosis, Biotechnology Research Laboratories, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Rosti V; Center for the Study and Treatment of Myelofibrosis, Biotechnology Research Laboratories, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Morreale G; Viticulture Research Center, Consiglio per la Ricerca e la sperimentazione in Agricoltura, Conegliano (TV), Italy.
Poletto V; Center for the Study and Treatment of Myelofibrosis, Biotechnology Research Laboratories, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Villani L; Center for the Study and Treatment of Myelofibrosis, Biotechnology Research Laboratories, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Bertorelli R; Laboratory of Biomolecular Sequence and Structure Analysis for Health, Fondazione 'Bruno Kessler', Trento (TN), Italy.
Pedrazzini M; Cardiovascular Genetics Laboratory, Biomedical and Technology Research Centre, Istituto Auxologico Italiano, Cusano Milanino (MI), Italy.
Zorzetto M; Laboratory of Biochemistry and Genetics, Division of Pneumology, Department of Molecular Medicine, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Barosi G; Center for the Study and Treatment of Myelofibrosis, Biotechnology Research Laboratories, Fondazione IRCCS 'Policlinico San Matteo', Pavia (PV), Italy.
Pokaż więcej
Corporate Authors:
AGIMM investigators
Źródło:
PloS one [PLoS One] 2015 Jan 24; Vol. 10 (1), pp. e0116636. Date of Electronic Publication: 2015 Jan 24 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
RNA Splicing*
Janus Kinase 2/*genetics
Primary Myelofibrosis/*genetics
Cell Line ; Computational Biology ; Exons ; Gene Expression Profiling ; Humans ; Janus Kinase 2/chemistry ; Mutation ; Regression Analysis ; Sequence Deletion
Czasopismo naukowe
Tytuł:
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
Autorzy:
Barosi G; Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. />Poletto V
Massa M
Campanelli R
Villani L
Bonetti E
Viarengo G
Catarsi P
Klersy C
Rosti V
Pokaż więcej
Źródło:
PloS one [PLoS One] 2013; Vol. 8 (3), pp. e59791. Date of Electronic Publication: 2013 Mar 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Janus Kinase 2/*genetics
Primary Myelofibrosis/*genetics
Primary Myelofibrosis/*mortality
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Alleles ; Bone Marrow Cells ; Child ; Cohort Studies ; Female ; Genotype ; Heterozygote ; Homozygote ; Humans ; Male ; Middle Aged ; Mutation ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
Autorzy:
Barosi G; Laboratory of Clinical Epidemiology and Centre for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. />Rosti V
Bonetti E
Campanelli R
Carolei A
Catarsi P
Isgrò AM
Lupo L
Massa M
Poletto V
Viarengo G
Villani L
Magrini U
Pokaż więcej
Źródło:
PloS one [PLoS One] 2012; Vol. 7 (4), pp. e35631. Date of Electronic Publication: 2012 Apr 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis/*classification
Primary Myelofibrosis/*diagnosis
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Cohort Studies ; DNA Mutational Analysis ; Female ; Humans ; Janus Kinase 2/genetics ; Kaplan-Meier Estimate ; Logistic Models ; Male ; Middle Aged ; Mutation, Missense ; Phenotype ; Primary Myelofibrosis/genetics ; Primary Myelofibrosis/mortality ; Prognosis ; World Health Organization ; Young Adult
Czasopismo naukowe
Tytuł:
Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes.
Autorzy:
Villani, Laura
Carolei, Adriana
Rosti, Vittorio
Massa, Margherita
Campanelli, Rita
Catarsi, Paolo
Abbà, Carlotta
Gale, Robert Peter
Barosi, Giovanni
Pokaż więcej
Temat:
VENOUS thrombosis
MYELOFIBROSIS
DEATH rate
VASCULAR endothelial growth factors
Źródło:
Genes; Aug2021, Vol. 12 Issue 8, p1271, 1p
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies